Spironolactone, an aldosterone antagonist, has been demonstrated to decrease mortality in human patients when added to other cardiac therapies.
Can it also increase survival if added to the other conventional therapies of dogs with naturally occurring myxomatous mitral valve disease (MMVD)? This was evaluated on more than 200 dogs!
|